Sotrastaurin
- Generic Name
- Sotrastaurin
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N6O2
- CAS Number
- 425637-18-9
- Unique Ingredient Identifier
- 7I279E1NZ8
- Background
Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 13
- Registration Number
- NCT00615693
- Locations
- ๐บ๐ธ
University of Southern California Doheny Eye Institute, Los Angeles, California, United States
๐บ๐ธJohn Hopkins Hospital/Wilmer Eye Institute, Baltimore, Maryland, United States
๐บ๐ธUniversity of California, San Francisco, California, United States
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00572585
- Locations
- ๐ต๐ฑ
Novartis Investigative Site, Poznan, Poland
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
- Conditions
- Kidney Transplantation
- Interventions
- Drug: mycophenolic plus tacrolimus
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT00555789
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 13
- Registration Number
- NCT00545259
- Locations
- ๐จ๐ญ
Novartis investigative site, Zurich, Switzerland
๐ฎ๐นNovartis Investigative Site, Padova, Italy
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 311
- Registration Number
- NCT00504543
- Locations
- ๐ฆ๐ท
Argentina, Buenos Aires, Argentina
๐ง๐ชBelgium, Gent, Belgium
๐จ๐ณNovartis Investigative Site, Taipie, Taiwan
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
- Conditions
- Kidney Transplantation
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT00492869
- Locations
- ๐บ๐ธ
USC Medical Center, Los Angeles, California, United States
๐บ๐ธUniversity of Cincinnati, Dept of Internal Medicine, Cincinnati, Ohio, United States
๐บ๐ธUniversity of Colorado Health Science Center, Denver, Colorado, United States
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2008-08-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00416546
- Locations
- ๐จ๐ฆ
Novartis Investigative Site, Dorval, Quebec, Canada
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
- Conditions
- Healthy
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 16
- Registration Number
- NCT00409929
- Locations
- ๐จ๐ญ
Novartis Investigative Site, Bern, Switzerland
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT00403416
- Locations
- ๐จ๐ญ
Inselspital Bern, Bern, Switzerland
๐ฎ๐นAzienda Ospedaliera di Padova - Universita degli Studi, Padova, Italy
๐บ๐ธUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.